The use of faecal microbiota transplant as treatment for recurrent or refractory clostridioides difficile infection and other potential indications: second edition of joint british society of gastroenterology (BSG) and healthcare infection society (HIS) guidelines.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Mullish, B HMerrick, B
Quraishi, M N
Bak, A
Green, C A
Moore, D J
Porter, R J
Elumogo, N T
Segal, J P
Sharma, N
Marsh, B
Kontkowski, G
Manzoor, S E
Hart, A L
Settle, C
Keller, J J
Hawkey, P
Iqbal, T H
Goldenberg, S D
Williams, H R T
Publication date
2024-04-11Subject
Communicable diseases
Metadata
Show full item recordAbstract
The first British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS)-endorsed faecal microbiota transplant (FMT) guidelines were published in 2018. Over the past 5 years, there has been considerable growth in the evidence base (including publication of outcomes from large national FMT registries), necessitating an updated critical review of the literature and a second edition of the BSG/HIS FMT guidelines. These have been produced in accordance with National Institute for Health and Care Excellence-accredited methodology, thus have particular relevance for UK-based clinicians, but are intended to be of pertinence internationally. This second edition of the guidelines have been divided into recommendations, good practice points and recommendations against certain practices. With respect to FMT for Clostridioides difficile infection (CDI), key focus areas centred around timing of administration, increasing clinical experience of encapsulated FMT preparations and optimising donor screening. The latter topic is of particular relevance given the COVID-19 pandemic, and cases of patient morbidity and mortality resulting from FMT-related pathogen transmission. The guidelines also considered emergent literature on the use of FMT in non-CDI settings (including both gastrointestinal and non-gastrointestinal indications), reviewing relevant randomised controlled trials. Recommendations are provided regarding special areas (including compassionate FMT use), and considerations regarding the evolving landscape of FMT and microbiome therapeutics.Citation
Mullish BH, Merrick B, Quraishi MN, Bak A, Green CA, Moore DJ, Porter RJ, Elumogo NT, Segal JP, Sharma N, Marsh B, Kontkowski G, Manzoor SE, Hart AL, Settle C, Keller JJ, Hawkey P, Iqbal TH, Goldenberg SD, Williams HRT. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. J Hosp Infect. 2024 Jun;148:189-219. doi: 10.1016/j.jhin.2024.03.001. Epub 2024 Apr 11.Type
ArticleAdditional Links
http://www.sciencedirect.com/science/journal/01956701PMID
38609760Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.jhin.2024.03.001